Skip to main content
. 2018 Aug 30;10:477–491. doi: 10.2147/CEOR.S171560

Figure 1.

Figure 1

Model structure.

Notes: Initial population without secukinumab was based on national epidemiological data derived from ISTAT. Adult patients (aged ≥18 years) diagnosed with psoriasis, PsA, and AS and currently treated with a biologic treatment were included in the BIA. The number of current psoriasis, PsA, and AS patients treated with different biologic drugs was obtained from the market share data (IQVIA 2016, Novartis data-processing). In the BIA, a formulary without secukinumab was compared to one with secukinumab (new formulary). A 3-year time horizon was considered for the analysis: market share related to 2016 was used and projection for the following 3 years was adopted. *Market share could be different for indication.

Abbreviations: AS, ankylosing spondylitis; BIA, budget impact analysis; ISTAT, Italian National Statistical Institute; PMPY, per Member per Year; PsA, psoriatic arthritis; PsO, psoriasis.